Can computation validate the final scientific claim?

No. In-silico synergy does not establish efficacy or tolerability. Computation can prioritize and eliminate directions; final validation remains with the appropriate domain methods and accountable specialists.

When should the project stop or reframe?

Stop or reframe when the target-disease link is not robust, the mechanism lacks a discriminating prediction, tractability depends on unsupported assumptions, public data contradict the thesis, or the next credible validation belongs in a qualified experimental program.

Drug Discovery

Combination-Therapy Hypotheses: Mechanism Before Matrix

Published 2026-08-22 · Updated 2026-08-22

Answer in brief

Treat Combination-Therapy Hypotheses as a ranking problem rather than a request for certainty. Define the decision about which combination has a plausible, discriminating rationale worth testing, assemble pathway complementarity, resistance mechanisms, exposure, toxicity, schedule, interaction models, and alternatives, and test whether the preferred route still leads after you predict a mechanistic rescue or resistance pattern unique to the combination. The recommendation remains bounded by the evidence and accountable specialist validation.

Evidence status: Decision-method guide; not a completed investigation or final validation.

The decision this guide supports

which combination has a plausible, discriminating rationale worth testing

Why the problem is difficult

The article-specific identification challenge is whether the question “which combination has a plausible, discriminating rationale worth testing” can be resolved using pathway complementarity, resistance mechanisms, exposure, toxicity, schedule, interaction models, and alternatives, rather than merely restated in new language.

A falsifier-first workflow

Define the decision precisely: which combination has a plausible, discriminating rationale worth testing.
Build a source and data ledger around pathway complementarity, resistance mechanisms, exposure, toxicity, schedule, interaction models, and alternatives.
Compare the inherited route with a mechanistically distinct alternative and a constraint-based null.
Actively search for the strongest counterevidence relevant to this decision, including boundary cases and prior failures.
Run the lowest-cost discriminating challenge: predict a mechanistic rescue or resistance pattern unique to the combination.
Record pursue, reframe, or stop, the confidence level, the evidence ceiling, and who owns downstream validation.

Decision criteria

Decision impact: would the result materially change the choice about which combination has a plausible, discriminating rationale worth testing?
Evidence fit: does the available evidence—pathway complementarity, resistance mechanisms, exposure, toxicity, schedule, interaction models, and alternatives—directly address the decision rather than merely correlate with it?
Discrimination: does the preferred route predict an outcome a credible alternative does not?
Robustness: does the ranking survive the challenge “predict a mechanistic rescue or resistance pattern unique to the combination”?
Validation boundary: is the conclusion no stronger than the available sources, data and computation?

Supporting evidence

pathway complementarity, resistance mechanisms, exposure, toxicity, schedule, interaction models, and alternatives

Counterevidence

For this decision, a result from “predict a mechanistic rescue or resistance pattern unique to the combination” that reverses or flattens the ranking must remain visible even when it is commercially inconvenient.

Computation

Here computation earns its place only if it changes the choice about which combination has a plausible, discriminating rationale worth testing or exposes why the available evidence cannot resolve it.

Fastest falsifier

predict a mechanistic rescue or resistance pattern unique to the combination

When to stop or reframe

A decision-specific stop trigger is failure of the challenge “predict a mechanistic rescue or resistance pattern unique to the combination” without an independently supported alternative mechanism.

Evidence ceiling

In-silico synergy does not establish efficacy or tolerability.

Sources and starting points

Open Targets Platform — Integrated public evidence connecting therapeutic targets and diseases.
ChEMBL — Curated bioactivity information for compounds, assays, and targets.
ClinicalTrials.gov — Official registry and results database for clinical studies; registry records are not proof of efficacy.
PubMed — Primary biomedical literature discovery; individual studies require direct appraisal.
UniProt — Additional authoritative starting point selected for this decision area; applicability must be checked against the precise question.
AlphaFold Protein Structure Database — Additional authoritative starting point selected for this decision area; applicability must be checked against the precise question.

Continue the decision journey

Explore the full topic hub · Editorial standard · Scientific Oracle consulting

Frequently asked questions

What decision does “Combination-Therapy Hypotheses: Mechanism Before Matrix” help make?: It supports a bounded decision about which combination has a plausible, discriminating rationale worth testing. The framework keeps alternatives, evidence, counterevidence, uncertainty, and the fastest falsification test visible.
What is the fastest useful test?: predict a mechanistic rescue or resistance pattern unique to the combination
Can computation validate the final scientific claim?: No. In-silico synergy does not establish efficacy or tolerability. Computation can prioritize and eliminate directions; final validation remains with the appropriate domain methods and accountable specialists.
When should the project stop or reframe?: Stop or reframe when the target-disease link is not robust, the mechanism lacks a discriminating prediction, tractability depends on unsupported assumptions, public data contradict the thesis, or the next credible validation belongs in a qualified experimental program.